Letrozol Pharmakern

Letrozole, the active ingredient in Letrozol Pharmakern, is a aromatase inhibitor presented as an oral dosage form for oral use. It is employed in the hormonal management of breast cancer, specifically in postmenopausal women with hormone‑receptor positive disease, and in both early‑stage and metastatic settings.

GNH USA supplies Letrozol Pharmakern as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozol Pharmakern, an aromatase inhibitor, is used in several breast‑cancer treatment pathways. - Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen‑driven tumor growth. - Adjuvant treatment of early breast cancer: lowers the risk of disease recurrence after surgery. - Metastatic breast cancer: helps control disease progression and may extend survival.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint pain: aching or stiffness in joints. - Fatigue: persistent tiredness not relieved by rest. - Nausea: feeling of queasiness or urge to vomit. - Headache: mild to moderate head discomfort. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Severe liver injury: marked elevation of liver enzymes or jaundice. - Bone fracture: increased risk of osteoporosis‑related breaks. - Pulmonary embolism: sudden shortness of breath and chest pain. - Myocardial infarction: heart attack symptoms such as chest pressure. - Anaphylaxis: rapid onset of allergic reaction with airway compromise. - Elevated cholesterol: significant rise in blood lipid levels.

Patients should be monitored for specific safety concerns before and during therapy. - Bone health monitoring: assess bone mineral density regularly. - Liver function testing: check hepatic enzymes at baseline and periodically. - Cardiovascular risk assessment: evaluate for hypertension, hyperlipidaemia, and thrombotic history. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception in women of child‑bearing potential. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Letrozole may interact with other medicines that affect its metabolism or therapeutic outcomes.

Major Interactions (Avoid): - Estrogen replacement therapy: may counteract letrozole’s estrogen‑lowering effect. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): can markedly reduce plasma concentrations. - Strong CYP2C19 inhibitors (e.g., fluconazole): may increase exposure and risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Statins: potential for increased muscle toxicity. - SSRIs (e.g., fluoxetine): may modestly raise letrozole levels. - Glucocorticoids: possible additive effects on bone loss. - Oral contraceptives: generally ineffective in postmenopausal patients but may affect hormone balance if used off‑label.